Format

Send to

Choose Destination
Pharmacol Rev. 2016 Jan;68(1):3-19. doi: 10.1124/pr.114.009373.

Antibody Drug Conjugates for Cancer Therapy.

Author information

1
Department of Molecular Oncology, Genentech, South San Francisco, California polakis.paul@gene.com.

Abstract

Antibody drug conjugates (ADCs) constitute a family of cancer therapeutics designed to preferentially direct a cytotoxic drug to cells expressing a cell-surface antigen recognized by an antibody. The antibody and drug are linked through chemistries that enable release of the cytotoxic drug or drug adduct upon internalization and digestion of the ADC by the cell. Over 40 distinct ADCs, targeting an array of antigens and utilizing a variety of drugs and linkers, are undergoing clinical evaluation. This review primarily covers ADCs that have advanced to clinical investigation with a particular emphasis on how the individual targets, linker chemistries, and appended drugs influence their behavior.

PMID:
26589413
DOI:
10.1124/pr.114.009373
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center